Presentation is loading. Please wait.

Presentation is loading. Please wait.

KDM1B Expression in Richardson Breast 2

Published byElaine Daniella Black Modified over 5 years ago

Similar presentations

Presentation on theme: "KDM1B Expression in Richardson Breast 2"— Presentation transcript:

1 KDM1B Expression in Richardson Breast 2
P-value: 2.00E-9 Log2 median-centered intensity Ductal Breast Carcinoma Breast (7) (40) KDM1B Expression in TCGA Breast KDM1B Expression in TCGA Breast P-value: 1.67E-18 P-value: 3.38E-11 Log2 median-centered ratio Log2 median-centered ratio Invasive Ductal Breast Carcinoma Invasive Breast Carcinoma Breast Breast (61) (389) (61) (76) Oncoprint Altered in 107 (11%) of cases Case Set: All Tumors: All tumor samples (1002 samples) KDM1B 11% Amplification Homozygous Deletion mRNA Upregulation mRNA Downregulation Copy number alterations are putative

Download ppt "KDM1B Expression in Richardson Breast 2"

Similar presentations

Comparison of Selected Genes in Curtis Breast Grouped by Cancer and Normal Type log2 median-centered intensity 1. Breast (144) 2. Benign Breast Neoplasm.

Comparison of Selected Genes in Curtis Breast Grouped by Cancer and Normal Type log2 median-centered intensity 1. Breast (144) 2. Benign Breast Neoplasm.
1 Example of HMMs: copy number data. 2 DNA copy number is the number of copies of a genomic segment present in the cell. Copy numbers are measured in.

1 Example of HMMs: copy number data. 2 DNA copy number is the number of copies of a genomic segment present in the cell. Copy numbers are measured in.
Comparative Genomic Hybridization (CGH). Outline Introduction to gene copy numbers and CGH technology DNA copy number alterations in breast cancer (Pollack.

Comparative Genomic Hybridization (CGH). Outline Introduction to gene copy numbers and CGH technology DNA copy number alterations in breast cancer (Pollack.
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
Proteomics Informatics – Data Analysis and Visualization (Week 13)

Proteomics Informatics – Data Analysis and Visualization (Week 13)
Cancer. 2003 Estimated US Cancer Cases Cancer Incidence Rates for Women, USA.

Cancer Estimated US Cancer Cases Cancer Incidence Rates for Women, USA.
Miki Fuse 1, Satoko Kojima 2, Takeshi Chiyomaru 3, Hideki Enokida 3, Kazumori Kawakami 3, Hirofumi Yoshino 3, Nijiro Nohata 1, Yukio Naya 2, Tomohiko Ichikawa.

Miki Fuse 1, Satoko Kojima 2, Takeshi Chiyomaru 3, Hideki Enokida 3, Kazumori Kawakami 3, Hirofumi Yoshino 3, Nijiro Nohata 1, Yukio Naya 2, Tomohiko Ichikawa.
OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1, Apostolos Zaravinos 2, Thomas Vrekoussis 1, Maria.

OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1, Apostolos Zaravinos 2, Thomas Vrekoussis 1, Maria.
Maxwell Lee National Cancer Institute Center for Cancer Research High-dimension Data Analysis Group March 19, 2014 Integrated Studies Of Breast, Esophageal,

Maxwell Lee National Cancer Institute Center for Cancer Research High-dimension Data Analysis Group March 19, 2014 Integrated Studies Of Breast, Esophageal,
Microarray hybridization Usually comparative – Ratio between two samples Examples – Tumor vs. normal tissue – Drug treatment vs. no treatment – Embryo.

Microarray hybridization Usually comparative – Ratio between two samples Examples – Tumor vs. normal tissue – Drug treatment vs. no treatment – Embryo.
Have a positive role in cell division Have a negative role in cell division Have a role in the maintenance of DNA integrity Genes altered in cancer typically:

Have a positive role in cell division Have a negative role in cell division Have a role in the maintenance of DNA integrity Genes altered in cancer typically:
 We investigated for biomarkers that distinguish metastatic or recurring disease with non-metastatic disease, with a particular focus on breast cancer.

 We investigated for biomarkers that distinguish metastatic or recurring disease with non-metastatic disease, with a particular focus on breast cancer.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Novel Integrative Methods for Gene Discovery Associated.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Novel Integrative Methods for Gene Discovery Associated.
Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.

Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.
Supplemental Figure 1. Specificity of CCL2 and Fsp1 immunostaining of breast tumor tissues. Sections of invasive ductal carcinoma were incubated with primary.

Supplemental Figure 1. Specificity of CCL2 and Fsp1 immunostaining of breast tumor tissues. Sections of invasive ductal carcinoma were incubated with primary.
Homozygous deletions within chromosome 9q23.

Homozygous deletions within chromosome 9q23.
Volume 14, Issue 10, Pages (March 2016)

Volume 14, Issue 10, Pages (March 2016)
Cancer Genomics and Class Discovery

Cancer Genomics and Class Discovery
A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716
Lung squamous cell carcinoma

Lung squamous cell carcinoma

Similar presentations

Ads by Google